Adelphi Group

adelphigroup.com

The Adelphi Group provides a wide range of strategic support services and consulting for global pharmaceutical clients. Adelphi is dedicated to the healthcare sector, providing services across strategic marketing, marketing and business intelligence, real-world observational research and disease-specific programmes, health and economic outcomes, market access, pricing and reimbursement, value insight, multi-channel health communications, scientific services, medical education, and strategic product

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

news image

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More

MedTech, Industrial Impact

JANUX THERAPEUTICS SUBMITS IND APPLICATION FOR JANX008

Janux | December 29, 2022

news image

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to develop a diverse pipeline of novel immunotherapies. On December 27, 2022, the company announced that it had submitted an investigational new drug (IND) application for JANX008 to U.S. Food and Drug Administration, an EGFR-TRACTr in (SCCHN). The company is pleased to announce its second IND. It consid...

Read More

Medical

AMBAGON THERAPEUTICS LAUNCHES WITH $85 MILLION SERIES A TO ADVANCE PIONEERING MOLECULAR GLUE PLATFORM AND PROGRESS PIPELINE

Ambagon Therapeutics | January 07, 2022

news image

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...

Read More

Industrial Impact

NEW DATA REVEAL MOLECULAR DRIVERS OF THYROID EYE DISEASE (TED) MAY REMAIN ACTIVATED IN PATIENTS WITH LOW CLINICAL ACTIVITY SCORE (CAS)

Horizon | October 03, 2022

news image

Horizon Therapeutics plc announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting Sept. 30 – Oct. 3 in Chicago. TED is a progressive and potentially vision-threatening rare autoimmune disease, which has been historically characterized as biphasic: acute, which is traditionally believe...

Read More
news image

AI

LABCORP AND PATHAI EXPAND THEIR PARTNERSHIP TO ACCELERATE USE OF AI-POWERED PATHOLOGY

PathAI, Labcorp | March 09, 2021

PathAI, a global supplier of artificial intelligence-powered (AI-powered) innovation for use in pathology research, and Labcorp, a main global life sciences company, today declared the expanding of their essential organization in the field of AI-powered pathology. The coordinated effort expands on Labcorp's past investment in PathAI and the companies' cooperation on a progression of projects, remembering the deployment of PathAI algorithms for clinical trials oversaw by Labcorp Drug Deve...

Read More
news image

MedTech, Industrial Impact

JANUX THERAPEUTICS SUBMITS IND APPLICATION FOR JANX008

Janux | December 29, 2022

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to develop a diverse pipeline of novel immunotherapies. On December 27, 2022, the company announced that it had submitted an investigational new drug (IND) application for JANX008 to U.S. Food and Drug Administration, an EGFR-TRACTr in (SCCHN). The company is pleased to announce its second IND. It consid...

Read More
news image

Medical

AMBAGON THERAPEUTICS LAUNCHES WITH $85 MILLION SERIES A TO ADVANCE PIONEERING MOLECULAR GLUE PLATFORM AND PROGRESS PIPELINE

Ambagon Therapeutics | January 07, 2022

Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues. The financing was led by Nextech Invest. Ambagon was previously seeded by RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, and Mission BioCapital. Investors from the seed round joined th...

Read More
news image

Industrial Impact

NEW DATA REVEAL MOLECULAR DRIVERS OF THYROID EYE DISEASE (TED) MAY REMAIN ACTIVATED IN PATIENTS WITH LOW CLINICAL ACTIVITY SCORE (CAS)

Horizon | October 03, 2022

Horizon Therapeutics plc announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting Sept. 30 – Oct. 3 in Chicago. TED is a progressive and potentially vision-threatening rare autoimmune disease, which has been historically characterized as biphasic: acute, which is traditionally believe...

Read More